Market Research Logo

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Review, H2 2016

Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Review, H2 2016’, provides in depth analysis on Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted pipeline therapeutics.

The report provides comprehensive information on the Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.
  • Updated report will be delivered in 48 hours of order confirmation.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape for Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1)
    • The report reviews Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved in Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics and enlists all their major and minor projects
    • The report assesses Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news and deals related to Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) targeted therapeutics
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand the targeted therapy areas and indications for Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1)
    • Identify the use of drugs for target identification and drug repurposing
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) development landscape
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) Overview
Therapeutics Development
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Products under Development by Stage of Development
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Products under Development by Therapy Area
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Products under Development by Indication
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Pipeline Products Glance
Early Stage Products
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Products under Development by Companies
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Boehringer Ingelheim GmbH
LEO Pharma A/S
Takeda Pharmaceutical Company Limited
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Drug Profiles
ALB-127158(a) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-13483342 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-3857 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BI-186908 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize MCHR1 for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize MCHR1 for Weight Loss - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Dormant Projects
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Discontinued Products
Melanin Concentrating Hormone Receptor 1 (G Protein Coupled Receptor 24 or MCH 1R or Somatostatin Receptor Like Protein or GPR24 or SLC1 or MCHR1) - Featured News & Press Releases
Oct 03, 2011: AMRI Presents Final Phase I Clinical Studies Results Of Obesity Compound At 29th Annual Scientific Meeting Of Obesity Society
May 31, 2011: AMRI Announces Successful Completion Of Phase I Clinical Study Of Obesity Compound
May 19, 2011: AMRI To Present Phase I Clinical Results Of Obesity Compound At European Congress On Obesity
Jul 21, 2010: AMRI Initiates Phase I Study Of ALB-127158(a) For Treatment Of Obesity
Jun 02, 2009: AMRI Advances New Obesity Drug MCH-1 Receptor Antagonist Toward IND Submission
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Albany Molecular Research, Inc., H2 2016
Pipeline by AstraZeneca Plc, H2 2016
Pipeline by Boehringer Ingelheim GmbH, H2 2016
Pipeline by LEO Pharma A/S, H2 2016
Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Dormant Projects, H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report